Sol, Incanthera’s lead asset, is a proprietary topical formulation designed to deliver into the skin an active known to treat solar keratosis and prevent the formation of skin cancers.
Studies on Sol’s permeation across the skin barrier and safety profile on human skin, announced in September 2020, surpassed expectations, strengthening the technology’s commercial potential and valuation.
Incanthera introduced Sol to a number of potential commercial partners in 2020, and has now prioritised discussions with two global cosmetic companies to licence Sol’s technology to commercial partners.
We are also separately exploring working with potential partners to apply its expertise and technology to develop further targeted products.
This includes a partnership that could provide new sun factor protection technology being used in conjunction with Sol.
The patent protection surrounding Sol extends to 2040, following a filing in 2020.